Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Published byIsaac McCormick Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement."— Presentation transcript:

1 Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement. From: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8): doi: /annonc/mdv249 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 1. Use of threshold HR in the ESMO-MCBS exemplified for HR threshold of 0.65.
From: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8): doi: /annonc/mdv249 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

3 Figure 2. The correspondence between an HR value and the minimum absolute gain in months considered as beneficial according to the ESMO-MCBS by median survival (OS or PFS) for control. From: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol. 2015;26(8): doi: /annonc/mdv249 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement."

Similar presentations

From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Fig. 3 Evolutionary game types as a function of relatedness and synergy where each plot is a different social group size. The payoffs used to generate.

Fig. 3 Evolutionary game types as a function of relatedness and synergy where each plot is a different social group size. The payoffs used to generate.
Figure 1 Cumulative chance of pregnancy according to age at initiation of pregnancy seeking. The curves were drawn based on the following assumptions:

Figure 1 Cumulative chance of pregnancy according to age at initiation of pregnancy seeking. The curves were drawn based on the following assumptions:
Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Fig. 1 Flow chart of study selection

Fig. 1 Flow chart of study selection
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
From: Face Recognition is Shaped by the Use of Sign Language

From: Face Recognition is Shaped by the Use of Sign Language
Figure 2. Illustration of minimum cross-sectional area (a) and measurements for oropharynx and soft palate in sagittal plane (b, c). From: Airway volume.

Figure 2. Illustration of minimum cross-sectional area (a) and measurements for oropharynx and soft palate in sagittal plane (b, c). From: Airway volume.
Fig. 1. Geographic locations of Shenzhen and Dongguan

Fig. 1. Geographic locations of Shenzhen and Dongguan

Similar presentations

Ads by Google